Physician

Richard M Scher, D.O.

According to 2025 Medicare claims, Richard Scher, D.O. (NPI: 1043205313) practices hematology/oncology in the Lakewood-New Brunswick, NJ market, with the plurality of this provider's patient population coming from Monmouth, NJ. This provider's primary affiliated billing organization is REGIONAL CANCER CARE ASSOCIATES LLC (NPI: 1801850243; TIN: 223141761) and primary practice location at 07739-1166.

Scher's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 591 traditional Medicare patients, billed 151,003 HCPCS/CPT codes, and received $3,128,147 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 757 prescription claims across 128 beneficiaries totaling $1,809,092 in drug costs, led by Revlimid (Lenalidomide). DME data shows 123 claims. Open Payments data shows 9 records totaling $2,688. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $2,069,808 to $3,128,147. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $902,159 to $1,809,092. In contrast, DME billing represents a smaller volume and moved from a higher plateau to a lower plateau, from $18,664 to $4,925.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	652	142,716	$2,069,808
2016	642	139,835	$1,756,169
2017	583	140,227	$1,841,940
2018	538	149,305	$2,171,369
2019	426	158,751	$1,739,707
2020	351	117,989	$1,794,390
2021	392	124,002	$2,072,494
2022	501	150,584	$2,858,180
2023	505	145,849	$2,923,652
2024	591	151,003	$3,128,147

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	94	703	$902,159
2016	105	780	$1,082,900
2017	123	1,060	$1,837,045
2018	121	974	$1,912,469
2019	113	1,020	$2,029,161
2020	102	855	$2,061,387
2021	110	791	$2,038,699
2022	123	828	$2,205,535
2023	124	696	$1,627,102
2024	128	757	$1,809,092

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	33	461	$50,237
2016	N/R	260	$16,184
2017	N/R	471	$17,217
2018	N/R	361	$15,961
2019	N/R	356	$14,424
2020	N/R	153	$8,130
2021	N/R	282	$10,975
2022	N/R	280	$11,081
2023	N/R	131	$5,211
2024	N/R	123	$5,659

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	395	1,367	$101
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	124	363	$74
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	142	492	$13
36415	Insertion of needle into vein for collection of blood sample	430	1,585	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	458	1,878	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	49	1,148	$693,230
Cabometyx	Cabozantinib S-Malate	11	330	$273,559
Lenalidomide	Lenalidomide	13	364	$186,187
Xarelto	Rivaroxaban	87	4,680	$84,420
Imbruvica	Ibrutinib	12	360	$70,202

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
E0781	Ambulatory infusion pump, single or multiple channels, electric or battery operated, with administrative equipment, worn by patient	Y	N/R	15	$2,980
A4222	Infusion supplies for external drug infusion pump, per cassette or bag (list drugs separately)	N	N/R	36	$1,273
J9190	Injection, fluorouracil, 500 mg	N	N/R	36	$734
A4221	Supplies for maintenance of non-insulin drug infusion catheter, per week (list drugs separately)	N	N/R	36	$671

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	8	$2,688	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	1	$5,000	Cornerstone Specialty Network LLC

Explore More Providers

FAQ

What Medicare data is available for Richard M. Scher, D.O.?

Tedicare shows public-source Medicare data for Richard M. Scher, D.O. (NPI 1043205313), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Richard M. Scher, D.O. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Richard M. Scher, D.O.?

Richard M. Scher, D.O. is linked to REGIONAL CANCER CARE ASSOCIATES LLC (billing NPI 1801850243) in the available physician profile data.

Does Richard M. Scher, D.O. have Open Payments data?

Richard M. Scher, D.O. has 9 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.